ATE366116T1 - Verwendung von alpha-msh und epo zur herstellung eines arzneimittels zur prophylaxe oder behandlung von durch ischämischen zuständen bewirkten krankheiten - Google Patents
Verwendung von alpha-msh und epo zur herstellung eines arzneimittels zur prophylaxe oder behandlung von durch ischämischen zuständen bewirkten krankheitenInfo
- Publication number
- ATE366116T1 ATE366116T1 AT01927645T AT01927645T ATE366116T1 AT E366116 T1 ATE366116 T1 AT E366116T1 AT 01927645 T AT01927645 T AT 01927645T AT 01927645 T AT01927645 T AT 01927645T AT E366116 T1 ATE366116 T1 AT E366116T1
- Authority
- AT
- Austria
- Prior art keywords
- alpha
- msh
- epo
- treatment
- allergic
- Prior art date
Links
- 230000000302 ischemic effect Effects 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 abstract 3
- 230000000172 allergic effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 206010012434 Dermatitis allergic Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20126400P | 2000-05-02 | 2000-05-02 | |
| DKPA200001204 | 2000-08-11 | ||
| DKPA200001757 | 2000-11-22 | ||
| DKPA200100369 | 2001-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE366116T1 true ATE366116T1 (de) | 2007-07-15 |
Family
ID=27439821
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01927646T ATE378064T1 (de) | 2000-05-02 | 2001-05-02 | Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände |
| AT01927645T ATE366116T1 (de) | 2000-05-02 | 2001-05-02 | Verwendung von alpha-msh und epo zur herstellung eines arzneimittels zur prophylaxe oder behandlung von durch ischämischen zuständen bewirkten krankheiten |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01927646T ATE378064T1 (de) | 2000-05-02 | 2001-05-02 | Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP1286690B1 (de) |
| JP (1) | JP2003531863A (de) |
| AT (2) | ATE378064T1 (de) |
| AU (4) | AU5462601A (de) |
| CA (2) | CA2407797A1 (de) |
| DE (2) | DE60129221D1 (de) |
| NZ (1) | NZ522851A (de) |
| WO (2) | WO2001082953A2 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7410941B1 (en) | 1999-04-13 | 2008-08-12 | The Kenneth S. Warren Institute, Inc. | Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin |
| US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| CA2476538C (en) | 2002-01-09 | 2012-07-17 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| AT500929B1 (de) * | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | Pharmazeutische zubereitung die erythropoietin enthält |
| JP2006241043A (ja) * | 2005-03-02 | 2006-09-14 | Kirin Brewery Co Ltd | 炎症性肺疾患の予防及び治療薬 |
| AU2005335905C1 (en) | 2005-08-26 | 2011-12-22 | Abbvie Inc. | Therapeutically active alpha-MSH analogues |
| WO2007069839A1 (en) * | 2005-12-12 | 2007-06-21 | Kyungpook National University Industry-Academic Cooperation Foundation | Novel use of erythropoietin protein |
| EP2081562B1 (de) | 2006-09-20 | 2016-02-24 | The Board of Regents of The University of Texas System | Verfahren zur abgabe von flüchtigen anästhetika für die regionalanästhesie und/oder schmerzlinderung |
| JP5162751B2 (ja) * | 2007-01-17 | 2013-03-13 | 国立大学法人 宮崎大学 | 急性腎不全の検出方法 |
| WO2009033812A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent |
| CA2704726A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a defensin peptide as a therapeutic agent |
| AU2008297885A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of GLP-1 as a therapeutic agent |
| WO2009094459A1 (en) | 2008-01-22 | 2009-07-30 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
| CN111150837B (zh) * | 2020-02-11 | 2022-07-12 | 中国人民解放军陆军军医大学 | Epo在抗金黄色葡萄球菌感染药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH676425A5 (de) * | 1986-08-08 | 1991-01-31 | Univ Texas | |
| ES2206521T3 (es) * | 1994-11-03 | 2004-05-16 | Roche Diagnostics Gmbh | Utilizacion de la eritropoyetina en el tratamiento de artritis reumatoide. |
| TW586933B (en) * | 1996-06-20 | 2004-05-11 | Chugai Pharmaceutical Co Ltd | Compositions for treating liver-complaints using EPO |
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
| IL124015A0 (en) * | 1998-04-08 | 1999-01-26 | Yeda Res & Dev | Pharmaceutical compositions comprising a protein |
-
2001
- 2001-05-02 NZ NZ522851A patent/NZ522851A/en unknown
- 2001-05-02 CA CA002407797A patent/CA2407797A1/en not_active Abandoned
- 2001-05-02 EP EP01927645A patent/EP1286690B1/de not_active Expired - Lifetime
- 2001-05-02 EP EP01927646A patent/EP1286691B1/de not_active Expired - Lifetime
- 2001-05-02 DE DE60129221T patent/DE60129221D1/de not_active Expired - Lifetime
- 2001-05-02 JP JP2001579826A patent/JP2003531863A/ja active Pending
- 2001-05-02 AU AU5462601A patent/AU5462601A/xx active Pending
- 2001-05-02 DE DE60131393T patent/DE60131393D1/de not_active Expired - Lifetime
- 2001-05-02 AU AU2001254626A patent/AU2001254626B2/en not_active Ceased
- 2001-05-02 AT AT01927646T patent/ATE378064T1/de not_active IP Right Cessation
- 2001-05-02 WO PCT/DK2001/000304 patent/WO2001082953A2/en not_active Ceased
- 2001-05-02 CA CA002407785A patent/CA2407785A1/en not_active Abandoned
- 2001-05-02 WO PCT/DK2001/000303 patent/WO2001082952A2/en not_active Ceased
- 2001-05-02 AU AU2001254625A patent/AU2001254625B2/en not_active Ceased
- 2001-05-02 AU AU5462501A patent/AU5462501A/xx active Pending
- 2001-05-02 AT AT01927645T patent/ATE366116T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ522851A (en) | 2004-11-26 |
| EP1286691A2 (de) | 2003-03-05 |
| DE60131393D1 (de) | 2007-12-27 |
| CA2407785A1 (en) | 2001-11-08 |
| WO2001082953A3 (en) | 2002-08-01 |
| WO2001082952A2 (en) | 2001-11-08 |
| DE60129221D1 (de) | 2007-08-16 |
| AU2001254626B2 (en) | 2006-09-21 |
| EP1286691B1 (de) | 2007-11-14 |
| AU2001254625B2 (en) | 2006-02-02 |
| AU5462501A (en) | 2001-11-12 |
| ATE378064T1 (de) | 2007-11-15 |
| EP1286690B1 (de) | 2007-07-04 |
| JP2003531863A (ja) | 2003-10-28 |
| WO2001082952A3 (en) | 2002-04-18 |
| AU5462601A (en) | 2001-11-12 |
| WO2001082953A8 (en) | 2004-04-29 |
| CA2407797A1 (en) | 2001-11-08 |
| WO2001082953A2 (en) | 2001-11-08 |
| EP1286690A2 (de) | 2003-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60129221D1 (de) | Verwendung von alpha-msh und epo zur herstellung eines arzneimittels zur prophylaxe oder behandlung von durch ischämischen zuständen bewirkten krankheiten | |
| ATE478669T1 (de) | Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen | |
| ATE325612T1 (de) | Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen | |
| DE69535607D1 (de) | Zusammensetzung enthaltend Stickstoffoxid-donatoren und Methode zur Behandlung analer Krankheiten | |
| BR0007778A (pt) | Peptidila cetonas heterocìclicas úteis como inibidores de triptase | |
| ATE416761T1 (de) | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund | |
| BR0211062A (pt) | Combinações para o tratamento de distúrbios inflamatórios | |
| ATE446756T1 (de) | Arzneimittelkompositionen auf der basis von tiotropium, ciclesonide und einem betamimetikum zur behandlung von entzündlichen und/oder obstruktiven atemwegserkrankungen | |
| NO20054878L (no) | 2-Fenoksy- og 2-fenylsulfonamidderivater med CCR3-antagonistisk aktivitet for behandling av astma og andre inflammasjons- eller immunologiske forstyrrelser | |
| NO20005887D0 (no) | Forbindelser med IgE-påvirkende egenskaper | |
| DE602004012418D1 (de) | Piperazinderivate und anwendungsverfahren | |
| DE69830582D1 (de) | Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind | |
| ATE428711T1 (de) | Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3- cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon | |
| ATE390928T1 (de) | Zusammensetzungen zur behandlung von hauterkrankungen | |
| DE60027077D1 (de) | Reinigungszusammensetzung zur Behandlung und/oder Verbesserung von Schuppen, Dermatitis seborrhoeica, Psoriasis und Ekzemen und deren Symptomen | |
| UA86400C2 (ru) | Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа | |
| ATE344262T1 (de) | 2-heteroarylcarbonsäureamide | |
| NO20050718L (no) | Topikal behandling av hudsykdommer | |
| ECSP055844A (es) | Nuevos compuestos triciclicos | |
| ATE345788T1 (de) | Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber | |
| ECSP034470A (es) | 6.alfa.,9.alfa-difluor-17.alfa.- (2-furanilcarboxilo) oxy-11.beta.-hidroxi-16.alfa.-metil-3-oxo-androst-1,4,-diene-17-acido carbotiotico s-fluormetil ester como un agente anti-inflamatorio | |
| UA42719C2 (uk) | Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб | |
| ATE363923T1 (de) | Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit | |
| ATE322244T1 (de) | Verwendung von polyaminosäurederivaten zur behandlung von seborrhoe und verwandten hautstörungen | |
| ATE236615T1 (de) | Pharmazeutische zubereitung zur oralen anwendung enthaltend einen histamin-immunoglobulin komplex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |